These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 20227995)

  • 1. Oral ibandronate in metastatic bone breast cancer: the Florence University experience and a review of the literature.
    Meattini I; Bruni A; Scotti V; Livi L; De Luca Cardillo C; Galardi A; Cipressi S; Biti G
    J Chemother; 2010 Feb; 22(1):58-62. PubMed ID: 20227995
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bone pain reduction in patients with metastatic breast cancer treated with ibandronate-results from a post-marketing surveillance study.
    Diel IJ; Kurth AH; Sittig HB; Meden H; Maasberg M; Sandermann A; Bergner R
    Support Care Cancer; 2010 Oct; 18(10):1305-12. PubMed ID: 20151162
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Phase II trial evaluating the palliative benefit of second-line oral ibandronate in breast cancer patients with either a skeletal related event (SRE) or progressive bone metastases (BM) despite standard bisphosphonate (BP) therapy.
    Clemons M; Dranitsaris G; Ooi W; Cole DE
    Breast Cancer Res Treat; 2008 Mar; 108(1):79-85. PubMed ID: 17473981
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [The role of ibandronate in the daily oncological practice].
    Nagykálnai T
    Magy Onkol; 2006; 50(4):325-7. PubMed ID: 17216006
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ibandronate: its role in metastatic breast cancer.
    Cameron D; Fallon M; Diel I
    Oncologist; 2006; 11 Suppl 1():27-33. PubMed ID: 16971737
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-effectiveness of oral ibandronate versus IV zoledronic acid or IV pamidronate for bone metastases in patients receiving oral hormonal therapy for breast cancer in the United Kingdom.
    De Cock E; Hutton J; Canney P; Body JJ; Barrett-Lee P; Neary MP; Lewis G
    Clin Ther; 2005 Aug; 27(8):1295-310. PubMed ID: 16199254
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Review of ibandronate in the treatment of metastatic bone disease: experience from phase III trials.
    Tripathy D; Body JJ; Bergström B
    Clin Ther; 2004 Dec; 26(12):1947-59. PubMed ID: 15823760
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Improved quality of life after long-term treatment with the bisphosphonate ibandronate in patients with metastatic bone disease due to breast cancer.
    Diel IJ; Body JJ; Lichinitser MR; Kreuser ED; Dornoff W; Gorbunova VA; Budde M; Bergström B;
    Eur J Cancer; 2004 Jul; 40(11):1704-12. PubMed ID: 15251160
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oral ibandronate improves bone pain and preserves quality of life in patients with skeletal metastases due to breast cancer.
    Body JJ; Diel IJ; Bell R; Pecherstorfer M; Lichinitser MR; Lazarev AF; Tripathy D; Bergström B
    Pain; 2004 Oct; 111(3):306-312. PubMed ID: 15363874
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oral ibandronate is as active as intravenous zoledronic acid for reducing bone turnover markers in women with breast cancer and bone metastases.
    Body JJ; Lichinitser M; Tjulandin S; Garnero P; Bergström B
    Ann Oncol; 2007 Jul; 18(7):1165-71. PubMed ID: 17442659
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of ibandronate for the treatment of skeletal events in patients with metastatic breast cancer.
    Heras P; Kritikos K; Hatzopoulos A; Georgopoulou AP
    Eur J Cancer Care (Engl); 2009 Nov; 18(6):653-6. PubMed ID: 19552728
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Renal safety of ibandronate 6 mg infused over 15 min versus 60 min in breast cancer patients with bone metastases: a randomized open-label equivalence trial.
    Pivot X; Lortholary A; Abadie-Lacourtoisie S; Mefti-Lacheraf F; Pujade-Lauraine E; Lefeuvre C; Letessier S; Morvan P; Dür C; Frimat L
    Breast; 2011 Dec; 20(6):510-4. PubMed ID: 21727006
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oral ibandronate for the treatment of metastatic bone disease in breast cancer: efficacy and safety results from a randomized, double-blind, placebo-controlled trial.
    Tripathy D; Lichinitzer M; Lazarev A; MacLachlan SA; Apffelstaedt J; Budde M; Bergstrom B;
    Ann Oncol; 2004 May; 15(5):743-50. PubMed ID: 15111341
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ibandronate is effective in preventing skeletal events in patients with bone metastases from colorectal cancer.
    Heras P; Karagiannis S; Kritikos K; Hatzopoulos A; Mitsibounas D
    Eur J Cancer Care (Engl); 2007 Nov; 16(6):539-42. PubMed ID: 17944770
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of ibandronate in metastatic bone disease: review of clinical data.
    Bell R
    Oncologist; 2005; 10 Suppl 1():8-13. PubMed ID: 16264107
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Loading dose ibandronate versus standard oral ibandronate in patients with bone metastases from breast cancer.
    Macpherson IR; Bray C; Hopkins C; Hannon RA; Lewsley LA; Ritchie DM; Canney P
    Clin Breast Cancer; 2015 Apr; 15(2):117-27. PubMed ID: 25454689
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oral osteonecrosis associated with the use of ibandronate: report of a case and clinical implications.
    Migliorati CA; Armonis BN; Nicolatou-Galitis O
    Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2008 Jul; 106(1):e18-21. PubMed ID: 18585606
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase II study of loading-dose ibandronate treatment in patients with breast cancer and bone metastases suffering from moderate to severe pain.
    Altundag K; Dizdar O; Ozsaran Z; Ozkok S; Saip P; Eralp Y; Komurcu S; Kuzhan O; Ozguroglu M; Karahoca M
    Onkologie; 2012; 35(5):254-8. PubMed ID: 22868504
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ibandronate: efficacy in the treatment of metastatic bone disease.
    Diel IJ
    Future Oncol; 2005 Oct; 1(5):593-607. PubMed ID: 16556036
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Breast cancer: bisphosphonate therapy for metastatic bone disease.
    Body JJ
    Clin Cancer Res; 2006 Oct; 12(20 Pt 2):6258s-6263s. PubMed ID: 17062710
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.